CTSK expression is reported to govern breast tumor progression and prognosis by promoting extracellular matrix degradation and angiogenesis45; CD53 expression was significantly associated with distant metastasis-free survival in ER− breast cancer patients46; ADAM12 is proposed as a biomarker and drug target in breast cancer47. This evidence concerns the gene CD53 and breast cancer.